The Deal Is Dead. The Market Made Its Verdict Clear.

On May 22, 2026, Estée Lauder and Spanish fragrance house Puig issued a joint statement confirming they were walking away from merger talks. No deal. No $40 billion luxury beauty empire. Just two companies going their separate ways — and investors treated that news very differently depending on which stock they held.

Estée Lauder shares surged roughly 13% in early trading Friday, according to Reuters. Puig dropped roughly 14% on the same day — landing at the bottom of Europe's STOXX 600 index and posting what looked to be its worst single-day performance since going public in 2024.

The same news caused a 13-point jump for one party and a 14-point collapse for the other. The divergence reflects which company benefited from continued uncertainty over a deal.

Why Wall Street Never Wanted This Merger

When merger talks first went public in March, Estée Lauder's stock actually fell — a sign that investors questioned the strategic fit.

Analysts at Bank of America put it plainly in a note to clients: the end of talks "should be a positive catalyst for the stock, as the equity story pivots back to fundamentals driven by an improving beauty market backdrop in China and Travel Retail."

Investors worried that merging with Puig would distract Estée Lauder from its own turnaround. CEO Stéphane de La Faverie has been pushing a restructuring agenda that includes ramping up product launches, adding luxury price tiers, and boosting marketing across key markets. The company raised its annual profit forecast earlier this month and announced plans to cut up to 3,000 more jobs globally, targeting $1 billion to $1.2 billion in gross cost savings by the end of fiscal 2027.

A company in the midst of restructuring may have found a $40 billion acquisition difficult to absorb.

Puig's Real Problem: The Fragrance Boom Is Fading

For Puig, the collapse of this deal exposes slower underlying performance that the merger speculation may have masked.

According to J.P. Morgan, cited by Reuters, investor attention will now return to operating results — and those results show fragrance market growth normalizing while pressure persists in the Middle East and travel retail channels. Puig's first-quarter update from April pointed to slower sales growth.

Puig's shares had rallied when the merger talks became public in March. Most of those gains are now gone, suggesting the market was pricing in deal optimism rather than confidence in Puig's standalone business.

The company said in Thursday's statement it would stay focused on executing its strategy and that its capital structure gives it "flexibility for selective mergers and acquisitions." Puig declined further comment when contacted by Reuters.

The Charlotte Tilbury Strain — What Most Coverage Is Burying

Bloomberg's coverage referenced "Tilbury Strain" — a detail most outlets have downplayed. Charlotte Tilbury Beauty is one of Puig's marquee acquisitions, a prestige makeup brand the Spanish company bought a majority stake in back in 2020. Reports suggested strain around that brand complicated the merger negotiations.

Puig didn't comment on specifics. If one of your flagship acquired brands creates friction at the negotiating table, it points to internal disputes over valuation or performance that the public hasn't gotten a straight answer on.

What's Really Happening Here

Most business press is framing this as a simple "deal fell through" story. The divergence between the two stocks tells a more complex story.

Estée Lauder got a vote of confidence from markets by walking away from a deal that would have complicated its recovery. Puig, a Spanish company that went public just a year ago with strong momentum tied to merger speculation, is now facing scrutiny it apparently wasn't eager to confront.

Puig's reliance on merger talk as a stock price support so soon after its IPO raises questions. The fragrance sector cooling off after years of explosive post-pandemic growth means Puig's organic growth story just got harder to sell.

What This Means for Shareholders and Consumers

Estée Lauder investors should benefit in the short to medium term. The company can now focus on restructuring without a massive acquisition complicating the process.

Puig shareholders face a fragrance-heavy portfolio dealing with market normalization, geographic headwinds, and the evaporation of a deal premium. J.P. Morgan's caution signals real concern.

For consumers buying perfume or lipstick, none of this changes anything. But the dynamic reveals something about luxury beauty: mergers are sometimes more about propping up share prices than building better companies.

The market figured that out fast.